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Abstract
Background: Caspase-8 is a key upstream mediator in death receptor-mediated apoptosis and also participates in
mitochondria-mediated apoptosis via cleavage of proapoptotic Bid. However, the role of caspase-8 in p53- and
p73-dependent apoptosis induced by genotoxic drugs remains unclear. We recently reported that the
reconstitution of procaspase-8 is sufficient for sensitizing cisplatin- but not etoposide-induced apoptosis, in
chemoresistant and caspase-8 deficient HOC313 head and neck squamous cell carcinoma (HNSCC) cells.
Results: We show that p53/p73-dependent caspase-8 activation is required for sensitizing etoposide-induced
apoptosis by utilizing HOC313 cells carrying a temperature-sensitive p53G285K mutant. Restoration of wild-type
p53 function under the permissive conditions, together with etoposide treatment, led to substantial transcriptional
activation of proapoptotic Noxa and PUMA, but failed to induce apoptosis. In addition to p53 restoration, caspase-
8 reconstitution was needed for sensitization to etoposide-induced apoptosis, mitochondria depolarization, and
cleavage of the procaspases-3, and -9. In etoposide-sensitive Ca9-22 cells carrying a temperature-insensitive mutant
p53, siRNA-based p73 knockdown blocked etoposide-induced apoptosis and procaspase-8 cleavage. However,
induction of p73 protein and up-regulation of Noxa and PUMA, although observed in Ca9-22 cells, were hardly
detected in etoposide-treated HOC313 cells under non-permissive conditions, suggesting a contribution of p73
reduction to etoposide resistance in HOC313 cells. Finally, the caspase-9 inhibitor Ac-LEHD-CHO or caspase-9 siRNA
blocked etoposide-induced caspase-8 activation, Bid cleavage, and apoptosis in both cell lines, indicating that p53/
p73-dependent caspase-8 activation lies downstream of mitochondria.
Conclusions: we conclude that p53 and p73 can act as upstream regulators of caspase-8, and that caspase-8 is an
essential mediator of the p53/p73-dependent apoptosis induced by etoposide in HNSCC cells. Our data suggest
the importance of caspase-8-mediated positive feedback amplification in the p53/p73-dependent apoptosis
induced by etoposide in HNSCC cells.
Background
Apoptosis or programmed cell death plays an essential
role in the development and homeostasis of multicellu-
lar organisms [1,2]. Because many anticancer drugs kill
tumor cells by inducing apoptosis, mutations or dysre-
gulation of pro- and anti-apoptotic proteins can contri-
bute to the acquisition of chemoresistance.
Two major apoptotic pathways have been defined in
mammalian cells: the extrinsic death receptor pathway
and the intrinsic mitochondrial pathway [3,4]. The
extrinsic pathway is initiated by the binding at the
plasma membrane of death ligands (e.g. FasL, TNF-a,
TRAIL) to their death receptors, which belong to the
tumor necrosis factor (TNF) receptor superfamily mem-
bers (e.g. Fas/Apo1, KILLER/DR5, TNF-RI, TRAIL
receptor). In contrast, the intrinsic pathway is initiated
by signals from within the cell to induce the apoptotic
process via the release of cytochrome c and other pro-
apoptotic proteins from mitochondria. Apoptosis is exe-
cuted by a family of cysteine-dependent aspartate-direc-
ted proteases (caspases). Based on their function,
caspases are classified into two groups, initiator caspases
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pase-3, -6, and -7). Caspase-8 is predominantly activated
by signals from the death receptor pathway, while cas-
pase-9 activation is dependent primarily on the mito-
chondrial pathway. In both apoptotic pathways, these
initiator caspases activate downstream effector caspases
(e.g. caspases-3, -6, -7) by a proteolytic cascade, result-
ing in the cleavage of a variety of cellular substrates
involved in apoptosis.
Although the apoptosis induced by genotoxic drugs is
generally thought to be dependent on mitochondria-
mediated caspase-9 activation, a number of studies have
reported caspase-8 activation during drug-induced apop-
tosis [5-22]. Drug-induced caspase-8 activation has been
shown to occur not only via the death receptor pathway,
but also via the mitochondrial pathway [11-22]. Cas-
pase-8 can be activated downstream of caspase-9,
through caspases-3 and -6, independently of death
receptor signalling [17-19,23]. Furthermore, caspase-8
can amplify the death signal by activating the mitochon-
drial pathway through the cleavage of the BH3-only pro-
tein Bid [14,24-30]. Cleaved Bid (tBid) translocates to
the mitochondria and then triggers mitochondrial depo-
larization, leading to cytochrome c release and subse-
quent caspase-9 activation, by which the activation of
caspase-8 initiates a positive feedback loop that amplifies
the mitochondrial pathway.
The p53 family proteins (p53, p63, and p73) regulate
apoptotic pathways upstream of caspases in response to
genotoxic drugs through transcriptional activation of
proapoptotic genes, the products of which participate in
the major apoptotic pathways: TNF receptor superfamily
members (Fas/Apo1 and KILLER/DR5) in the death
receptor pathway, and pro-apoptotic Bcl-2 family mem-
bers (Bax, Puma, Noxa and Bid) in the mitochondrial
pathway [31-34]. Transcriptionally independent func-
tions of p53 also affect the mitochondrial pathway, as
p53 localizes either in the cytosol or at the mitochon-
dria, triggering mitochondrial depolarization via activa-
tion of Bax or Bak [35]. Recent studies of the p53 family
members p63 and p73 have indicated that p53, p63 and
p73 jointly mediate cellular responses to genotoxic
drugs [36]. TA-p73 is induced by a variety of drugs and
can compensate for deficient p53 function so as to
induce apoptosis in p53-deficient tumors [37-39].
Although p63 and p73 gene mutations are rare, it has
been reported that p63 levels and p73 status are impor-
tant determinants of responsiveness to cytotoxic drugs
in HNSCC [38-40]. Nevertheless, the precise mechan-
isms by which p53 family members regulate caspase
activation during drug-induced apoptosis are not pre-
sently well understood.
Previously, we examined the functional relevance of
caspase-8 in drug-induced apoptosis by using the p53-
mutated HOC313 HNSCC cell line, which is highly
resistant to TRAIL and chemotherapeutic drugs, includ-
ing cisplatin and etoposide [41,42]. We found a biallelic
caspase-8 nonsense mutation that led to the truncation
of all of its defined functional domains in HOC313 cells.
Reconstitution of caspase-8 by stable transfection of
wild-type procaspase-8 sensitized the cells to cisplatin-
induced apoptosis, in parallel with cisplatin-induced up-
regulation of TNF-a and TRAIL mRNA. However,
while caspase-8 activation by etoposide treatment has
been described in other types of cells [11,19-22], cas-
pase-8 reconstitution was insufficient to sensitize
HOC313 cells to etoposide-induced apoptosis in the
HOC313 cell line, suggesting additional mechanisms of
resistance to etoposide in this cell line.
Given the importance of p53 as an upstream regulator
of caspase activation, we hypothesized that p53 and its
family members may be involved in caspase-8 activation
and the induction of apoptosis by etoposide in HNSCC
cells. In this study, we explored the functional relevance
of caspase-8 and the p53 status in etoposide-induced
apoptosis by using two HNSCC cell lines: an etoposide-
resistant HOC313 cell line that is deficient in caspase-8
which carries the temperature-sensitive mutant
p53G285K; and etoposide-sensitive Ca9-22 cell line that
expresses wild-type caspase-8 and the p53R248W
mutant, which has no recognizable temperature-sensi-
tive properties. Our data demonstrate a critical role for
p53/p73-dependent caspase-8 activation in etoposide-
induced apoptosis in HNSCC cells.
Results
The restoration of wild-type p53 function induced p53-
target gene expression in etoposide-treated HOC313 cells
We previously reported that stable caspase-8 reconstitu-
tion sensitizes drug-resistant and caspase-8-deficient
HOC313 cells to cisplatin-induced apoptosis [42]. How-
ever, caspase-8 reconstitution was insufficient to sensi-
tize HOC313 cells to apoptosis induced by etoposide.
To explore the mechanisms underlying etoposide resis-
tance in HOC313 cells, we examined the role of p53
function in etoposide-induced apoptosis by temperature-
downshift experiments, as HOC313 cells express the
endogenous mutant p53G285K protein which has been
shown to have temperature-sensitive properties [43].
CAT reporter assays confirmed that transfection of
Saos-2 cells with a plasmid expressing p53G285K led to
a 32.3-fold increase in the transactivation of a p53
reporter gene containing p53-responsive elements at
32.5°C, while no activation (0.9-fold) was observed at
37°C. Furthermore, quantitative real-time RT-PCR ana-
lysis of p53-target genes revealed that a temperature
downshift to 32.5°C resulted in a 22-fold increase com-
pared to the untreated control in mRNA expression of
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Waf1/Cip1 gene, a critical mediator of p53-induced
cell-cycle arrest, in etoposide- but not cisplatin-treated
HOC313 cells (Figure 1A). This occurred in parallel
with induction of p21
Waf1/Cip1 protein as demonstrated
by Western blotting (Figure 1B). This temperature
downshift also led to 17- and 4.5-fold increases of proa-
poptotic PUMA and Noxa transcripts, respectively, in
etoposide- but not cisplatin-treated HOC313 cells, as
compared to the untreated controls. In Ca9-22 cells,
which express the temperature-insensitive p53R248W
mutant, etoposide, but not cisplatin treatment led to up-
regulation of p21, PUMA and Noxa transcription
equally at both temperatures (Figure 1A).
Numerous studies have demonstrated that phosphory-
lation of p53 at specific N-terminal serines in response
to DNA damage contributes to increase the stability and
activity of p53 [31-34]. Among them, ser46 phosphoryla-
tion has been reported to enhance p53-mediated tran-
scriptional activation of pro-apoptotic genes [44]. While
the temperature downshift alone led to a slight increase
of p53-target gene expression in HOC313 cells (Figure
1A), it did not induce Ser46 phosphorylation in the
absence of drug treatment (Figure 1B). Etoposide and,
to a lesser extent, cisplatin treatment caused ser46 phos-
phorylation following the temperature downshift in
HOC313 cells, while each of the drugs induced ser15
phosphorylation at both temperatures. Notably, ser46
phosphorylation of the p53G285K protein was hardly
detected after drug treatment at 37°C in HOC313 cells,
w h i c hi sc o n s i s t e n tw i t hp r e v i o u so b s e r v a t i o n st h a ta
certain type of mutant p53 is not susceptible to drug-
induced Ser46 phosphorylation [45]. Collectively, these
data indicate that the temperature downshift to the per-
missive temperature (32.5°C) leads to the restoration of
mutant p53G285K to the wild-type p53 function,
thereby leading to transcriptional induction of p53-tar-
get genes in etoposide- but not cisplatin-treated
HOC313 cells. In addition, the fact that the expression
of p53-target genes was unaffected by cisplatin indicates
that these two drugs have distinct effects on p53-target
gene expression in HNSCC cell lines.
Both p53 restoration and caspase-8 reconstitution are
needed for sensitizing etoposide-induced apoptosis in
HOC313 cells
We examined whether the restoration of wild-type p53
function affects the chemosensitivity of HOC313 cells
by using drug-sensitive Ca9-22 cells as the control. Cell
viability assays under permissive and non-permissive
conditions revealed that p53 restoration by temperature
downshift to 32.5°C significantly sensitized HOC313
cells to etoposide, but not cisplatin (Figure 2A). How-
ever, the temperature downshift rendered Ca9-22 cells
to become slightly more resistant to both etoposide and
cisplatin.
We next investigated the functional role of caspase-8
in etoposide-induced apoptosis by using HOC313/c8_3
cells stably reconstituted for caspase-8 [42]. Laser scan-
ning cytometry (LSC) analysis showed that p53 restora-
tion resulted in no increase of the sub-G1 population in
either the cisplatin- or etoposide-treated parent
HOC313 cells (Figure 2B). By contrast, in HOC313/c8_3
cells, p53 restoration induced apoptosis (sub-G1 popula-
tion = 57%) after etoposide treatment, while cisplatin
induced apoptosis without the temperature downshift,
as reported previously [42]. In addition, no induction of
apoptosis and Ser46 phosphorylation (Figure 1B) by the
temperature downshift in the absence of drug treatment
indicates that the temperature downshift by itself is
insufficient to fully activate the restored p53G285K
Figure 1 The restoration of wild-type p53 function induced
p53-target gene expression in etoposide-treated HOC313 cells.
A, cells treated with cisplatin (10 μg/ml) or etoposide (100 μg/ml)
were incubated at 32.5°C or 37°C for 6 h; the amount of mRNA
encoding PUMA, Noxa and p21 was measured using real-time RT-
PCR. n > 3 for all conditions. Bars, SD. B, p53 phosphorylation and
p21 expression in drug-treated cells. Cells were treated with drugs
as in A for 24 hours followed by Western blot analysis with the
indicated antibodies. b-actin was used as a loading control.
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functions of both p53 and caspase-8 are required for the
sensitization to etoposide-induced apoptosis in HOC313
cells.
Both p53 and caspase-8 functions are needed for
etoposide-induced caspase activation in HOC313 cells
We examine the roles of p53 and caspase-8 functions in
the cleavage of procaspases and PARP, a marker of
apoptosis, by Western blotting. Consistent with the
results of LSC analysis, p53 restoration by temperature
downshift resulted in the cleavage of the transfected
Flag-tagged procaspase-8 as well as the cleavage of the
procaspases-3, and -9, and PARP following etoposide
treatment in caspase-8-reconstituted HOC313/c8_3 cells
(Figure 3A). However, no or little cleavage of these pro-
caspases and PARP was observed at 37°C. Furthermore,
while p53 restoration by itself induced the proapoptotic
gene transcription and Ser46 phosphorylation (Figure
1A and 1B), it induced only a weak cleavage of procas-
pase-9 and there was no detectable procaspase-3 clea-
vage in control HOC313/v_1 cells lacking functional
caspase-8. By contrast, cisplatin treatment led to clea-
vage in a manner independent of p53 restoration in
HOC313/c8_3 cells. Consistent with these results, p53
restoration resulted in an 8-fold increase of caspase-3/7
activity after etoposide treatment, whereas the activity
was increased regardless of p53 function after cisplatin
treatment (Figure 3B). These results demonstrate that
both caspase-8 and p53 functions are critical for etopo-
side-induced caspase-9 activation, and also the subse-
quent cleavage of procaspase-3 and PARP in HOC313
cells. To confirm the requirement of caspase-8 activity
in the etoposide-induced apoptosis, HOC313 cells were
transiently transfected with the empty vector, wild-type
(WT), or C360S inactive mutant of Flag-tagged caspase-
8 by electroporation, then treated with etoposide at
32.5°C. Transfection of caspase-8 (WT) induced apopto-
sis (sub-G1 population = 25%), whereas that of the cas-
pase-8 (C360S) mutant did not increase sub-G1
populations compared to the vector transfection (7% vs
9%) (Figure 3C).
p73 is responsible for etoposide-induced caspase-8
activation and apoptosis in drug-sensitive Ca9-22 cells
It has been shown that the p53 homologue p73 is
induced by genotoxic drugs, and plays a critical role in
p53-independent apoptosis in p53-deficient tumors
[37,38]. Etoposide treatment up-regulated the p53-target
genes in Ca9-22, but not in HOC313 cells under non-
permissive conditions (37°C) (Figure 1A). Therefore, we
examined the expression levels of the p73 protein fol-
lowing drug treatment in HOC313 and Ca9-22 cells.
Western blot analysis revealed that etoposide induced
the expression of p73a and p73b much more potently
than did cisplatin, accompanied by the cleavage of pro-
caspases-8 and -9 in Ca9-22 cells (Figure 4A). However,
induction of p73 was substantially reduced in HOC313
cells relative to Ca9-22 cells after treatment with either
etoposide or cisplatin.
The fact that p53R248W mutation in Ca9-22 cells is a
hotspot mutation resulting in loss of sequence-specific
DNA binding and apoptotic functions suggests that p73
plays a critical role in etoposide-induced apoptosis in
Ca9-22 cells. To test this possibility, we examined the
effects of p73 knockdown on etoposide-induced apopto-
sis in drug-sensitive Ca9-22 cells by using two p73 small
i n t e r f e r i n gR N A s( s i R N A s )t h a tt a r g e td i f f e r e n tp 7 3
Figure 2 Both p53 restoration and caspase-8 reconstitution are
needed to sensitize etoposide-induced apoptosis in HOC313
cells. A, effects of temperature downshift on the chemosensitivity of
HOC313 and Ca9-22 cells. Cells were treated with increasing doses
of cisplatin or etoposide at 32.5°C (solid circle) or 37°C (open
triangle) for 24 h. Cell viability was measured by WST-1 assay. The
results are the means ± SD from three independent experiments.
Bars, SD. The asterisk indicates a significant difference (p < 0.05)
between 32.5°C and 37°C (t-test). B, effects of temperature
downshift on the DNA profile of drug-treated HOC313 and
HOC313/c8_3 cells. Cells treated with cisplatin (10 μg/ml) or
etoposide (100 μg/ml) were incubated at 32.5°C or 37°C for 24 h,
followed by LSC analysis. The horizontal and vertical axes represent
the DNA content and cell number, respectively. The apoptotic cell
population is indicated as a percentage of the sub-G1 fraction.
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that siRNA-based p73 knockdown (Figure 4B, lower
panel) decreased the sub-G1 population in etoposide-
treated Ca9-22 cells, but had more subtle effects on cis-
platin-treated cells (Figure 4B, upper panel). The caspase
3 / 7a s s a y sp e r f o r m e d1 8h ra n d3 0h ra f t e rd r u g
treatment consistently indicated that p73 siRNA blocked
caspase 3/7 activity in etoposide- but not cisplatin-trea-
ted Ca9-22 cells (Figure 4C). Consistent with this, wes-
tern blotting verified that p73 siRNA blocked the
cleavage of procaspases-3, and -8 after etoposide, but
had no or very slight effects on the cleavage of these
Figure 3 Both p53 and caspase-8 functions are needed for etoposide-induced caspase acti v a t i o ni nH O C 3 1 3c e l l s . A, effects of
temperature downshift on the cleavage of the procaspases and PARP in drug-treated HOC313 cells and HOC313/c8_3 cells. The cells treated
with drugs as in Figure 2B were subjected to Western blotting for PARP, and the caspases-8, -9 and -3. b-actin was used as a loading control. B,
effects of temperature downshift on caspase 3/7 activities in drug-treated HOC313 cells and HOC313/c8_3 cells. The cells treated with drugs as
in Figure 2B for 12 h were subjected to Caspase-Glo 3/7 assay. Results are expressed as fold induction compared with untreated control. The
bars show the SD. The asterisk indicates a significant difference (p < 0.05) between 32.5°C and 37°C in etoposide-treated HOC313/c8_3 cells (t-
test). C, the caspase-8 (C360S) mutant did not induced apoptosis in etoposide-treated HOC313 cells at 32.5°C. HOC313 cells were transiently
transfected with the indicated expression vectors by electroporation. Twenty-four hours after transfection, cells were treated with etoposide (100
μg/ml) at 32.5°C. DNA profiles were analyzed 40 h after drug treatment as in Figure 2B (left panel). Caspase-8 expression was analyzed by
Western blot using anti-FLAG antibody 24 h after drug treatment (right panel).
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Page 5 of 13Figure 4 p73 is responsible for etoposide-induced caspase-8 activation and apoptosis in drug-sensitive Ca9-22 cells. A, the induction of
endogenous p73 following drug treatment. Cells treated with the drugs as in Figure 2B were subjected to Western blotting with p73, caspase-8
or caspase-9 antibodies. B, C and D, Ca9-22 cells were transfected with either p73 or control siRNA. At 48 h after siRNA transfection, cells were
treated with cisplatin (5 μg/ml) or etoposide (50 μg/ml). DNA profiles were analyzed by LSC 30 h after drug treatment (B, upper panel). The
horizontal and vertical axes represent the DNA content and cell number, respectively. Apoptotic cell population is indicated as a percentage of
the sub-G1 fraction. p73 expression was analyzed by Western blot 30 h after drug treatment (B, lower panel). Caspase 3/7 activity was analyzed
at the indicated time after drug treatment (C). Results are expressed as fold induction compared with untreated control. The bars represent the
SD. The asterisk indicates a significant difference (p < 0.05) between p73 siRNA-1 and control siRNA treatment cells (t-test). The cleavage of
procaspases was analyzed by western blot with caspases-3 and -8 antibodies 24 h after drug treatment (D). E and F, Ca9-22 cells were
transfected with either caspase-8 or control siRNA. At 48 h after siRNA transfection, cells were treated with etoposide (100 μg/ml). DNA profiles
were analyzed by LSC 24 h after drug treatment as in B (E). The expression and cleavage of procaspases and Bid was analyzed by western blot
with caspases-3, -8, -9, and Bid antibodies 24 h after drug treatment (F). b-actin was used as a loading control.
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Furthermore, caspase-8 knockdown by siRNA blocked
etoposide-induced apoptosis (Figure 4E) and also the
cleavage of procaspase-9 and -3 in Ca9-22 cells (Figure
4F), confirming that caspase-8 activity is required for
etoposide-induced apoptosis in Ca9-22 cells. Collec-
tively, these results indicate that p73 is responsible for
etoposide- but not cisplatin-induced caspase-8 activation
and apoptosis in p53-deficient Ca9-22 cells, and suggest
that reduction of p73 expression, at least in part, contri-
butes to etoposide resistance in HOC313 cells.
Caspase-9 is functionally relevant in caspase-8 activation
and the induction of apoptosis by etoposide
The results presented above indicate that p53/p73 func-
tions are required for etoposide-induced caspase-8 acti-
vation and apoptosis in the HNSCC cell lines. Caspase
activation by p53/p73 occurs through the activation of
the mitochondrial pathway, leading to the activation of
caspase-9. Furthermore, caspase-8 can be activated
downstream of caspase-9 by the activated caspases-3
and -6. To explore the mechanisms of p53/p73-depen-
dent caspase-8 activation and the apoptosis induced by
etoposide, we examined the functional role of caspase-9
in these events by using Ac-IETD-CHO or Ac-LEHD-
CHO, two peptide inhibitors specific for caspases-8 and
-9, respectively. Consistent with the results of caspase-8
knockdown (Figure 4E), LSC analysis confirmed that the
caspase-8 inhibitor blocked the apoptosis induced
by etoposide in Ca9-22 and p53-restored (32.5°C)
HOC313/c8_3 cells (Figure 5A). Importantly, the cas-
pases-9 inhibitor also blocked etoposide-induced
apoptosis in both cell lines. Furthermore, enzymatic
measurement of caspase-8 activities revealed that the
caspase-9 inhibitor blocked etoposide-induced caspase-8
activation in both cell lines, indicating the requirement
of caspase-9 function for caspase-8 activation induced
by etoposide (Figure 5B). However, the caspases-9 inhi-
bitor had only a slight effect on caspase-8 activation by
cisplatin, which is consistent with our previous observa-
tions that cisplatin activates caspase-8 via the death
receptor pathway in these cell lines [42].
The requirement of caspase-9 in etoposide-induced
caspase-8 activation and apoptosis was further con-
firmed by transfection with two caspase-9 siRNAs that
target two different caspase-9 sequences (caspase-9
siRNA-1 and -2) into Ca9-22 and HOC313/c8_3 cells.
LSC analysis revealed that caspase-9 siRNA (Figure 6A)
decreased the sub-G1 populations in the Ca9-22 and
p53-restored HOC313/c8_3 cells treated with etoposide
(Figure 6B). This was paralleled by the inhibition of cas-
pase-8 cleavage by caspase-9 siRNA, as demonstrated by
Western blotting (Figure 6C). Collectively, these results
demonstrate that p53/p73-dependent caspase-8
activation and apoptosis induction by etoposide are
mediated through the activation of the mitochondrial
pathway in these HNSCC cell lines.
Caspase-8 reconstitution activates the p53-mediated
mitochondrial pathway induced by etoposide
It has been reported that activation of caspase-8 initiates
a positive feedback loop that amplifies the mitochondrial
pathway via cleavage of proapoptotic Bid, leading to
depolarization of the mitochondria and subsequent cas-
pase-9 activation. As showni nF i g u r e7 A ,e t o p o s i d e
treatment induced the cleavage of Bid into tBid in Ca9-
22 cells, and etoposide treatment, together with p53
restoration at 32.5°C, led to Bid cleavage in caspase-8
reconstituted HOC313/c8_3 cells in parallel with the
cleavage of the procaspases-3, and -8, -9. Furthermore,
caspase-9 siRNA suppressed etoposide-induced cleavage
of Bid in Ca-9-22 cells (Figure 6C). Finally, we examined
the alteration of the mitochondrial membrane potential
(ΔΨm) of HOC313/v_1 and HOC313/c8_3 cells follow-
ing drug treatment by JC-1 assay. Figure 7B shows that
Figure 5 Caspase-9 is functionally relevant in etoposide-
induced caspase-8 activation and apoptosis. A and B, effects of
caspase inhibitors on caspase-8 activation and the induction of
apoptosis by etoposide in HNSCC cell lines. HOC313/c8_3 cells and
Ca9-22 cells were incubated at 32.5°C and 37°C respectively with
the indicated caspase inhibitors (80 μM) for 1.5 h, followed by
treatment with cisplatin (10 μg/ml) or etoposide (100 μg/ml) for 24
h. The DNA profiles were analyzed by LSC as in Figure 2B (A).
Caspase-8 activity was analyzed by Caspase-Glo 8 assay (B). Results
are expressed as fold induction compared with untreated control.
The bars represent the SD. The asterisk indicates a significant
difference (p < 0.05) between the presence and absence of Ac-
LEHD-CHO in etoposide-treated cells (t-test).
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the reduction of ΔΨm (48%) in caspase-8-reconstituted
HOC313/c8_3, but not in HOC313/v_1 cells, whereas
cisplatin treatment had a little effect on the ΔΨma t
either temperature. Taken together, these results indicate
that caspases-8 plays a critical role in etoposide-induced
p53-dependent depolarization of the mitochondria.
Discussion
While caspase-8 and the p53 family members play critical
roles in triggering apoptosis induced by genotoxic drugs,
the functional relevance of caspase-8 in p53/p73-depen-
dent apoptosis has not been fully understood. In the pre-
sent study, we investigated the relationship of caspase-8
and the p53 status with drug-induced apoptosis in
HNSCC cells. A capase-8 deficient HOC313 cell line
carrying temperature-sensitive p53G285K mutant was
a useful tool to address this issue. Here, we provide
evidence that caspase-8 is an essential mediator of the
p53/p73-dependent apoptosis induced by etoposide in
HNSCC cells.
The different lines of experiments clearly demonstrate
the functional relevance of caspase-8 in p53/p73-depen-
dent apoptosis induced by etoposide in HNSCC cells.
First, the restoration of p53 function, by itself, induced
proapoptotic PUMA and Noxa, but did not activate
casapases-3 and -9 or induce apoptosis in HOC313 cells
following etoposide treatment. However, in addition to
p53 restoration, caspase-8 reconstitution was required
for sensitizing etoposide-induced apoptosis, mitochon-
drial depolarization, and the cleavage of procaspases-3,
-9, and Bid in HOC313 cells. Second, in drug-sensitive
Figure 6 Caspase-9 is functionally relevant in etoposide-
induced caspase-8 activation and apoptosis. A and B, cells were
transfected with either caspase-9 or control siRNA. At 48 h after
siRNA transfection, cells were treated with cisplatin (10 μg/ml) or
etoposide (100 μg/ml). Caspase-9 expression was analyzed by
Western blot 24 h after drug treatment (A). The DNA profiles were
analyzed by LSC 24 h after drug treatment (B). The horizontal and
vertical axes represent the DNA content and cell number,
respectively. Apoptotic cell population is indicated as a percentage
of the sub-G1 fraction. The cleavage of procaspase-9 and Bid was
analyzed by Western blot with caspases-9 and Bid antibodies 24 h
after drug treatment (C). b-actin was used as a loading control.
Figure 7 Caspase-8 reconstitution activates the p53-mediated
mitochondrial pathway induced by etoposide. A, cleavage of
procaspase-9 and Bid were analyzed by Western blot with caspase-9
and Bid antibodies 24 h after drug treatment. Exo and endo
represent exogenous and endogenous, respectively. B, effects of
drug treatment on the mitochondrial membrane potential (ΔΨm) in
HOC313/v_1 and HOC313/c8_3 cells at 32.5°C or 37°C. Cells treated
with cisplatin (10 μg/ml) or etoposide (100 μg/ml) for 10 h were
subjected to JC-1 assay as described in Materials and methods. To
measure ΔΨm, the ratio of red to green fluorescence of JC-1 was
calculated for each sample and compared with the untreated
control JC-1 fluorescence ratio at each temperature. Results are the
means ± SD from three independent experiments. The bars
represent the SD. The asterisk indicates a significant difference (p <
0.05) between 32.5°C and 37°C in etoposide-treated HOC313/c8_3
cells (t-test).
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Page 8 of 13Ca9-22 cells, p73 siRNA blocked etoposide-induced
apoptosis, caspase-8 cleavage, and caspase-3/7 activa-
tion, which correlated with the observed reduction of
p73 expression in etoposide-resistant HOC313 cells.
Finally, both the caspase-8 inhibitor Ac-IETD-CHO and
caspase-8 siRNA inhibited etoposide-induced apoptosis
in Ca9-22 cells. The consistency on the results obtained
from both the etoposide-resistant HOC313 and etopo-
side-sensitive Ca9-22 HNSCC cell lines suggests that
our results may reflect characteristics of HNSCC cells,
rather than a cell-type-specific phenomenon that occurs
only in HOC313 cells. Although drug-induced caspase-8
activation in death receptor-independent apoptosis has
been reported in several types of cells, our data demon-
strate that p53 and p73 act as key upstream regulators
of caspase-8 in etoposide-induced apoptosis in HNSCC
cells. In agreement with this, etoposide treatment led to
up-regulation of the proapoptotic p53-target genes
PUMA and Noxa in both Ca9-22 and p53-restored
HOC313 cells. Furthermore, neither death ligand nor
death receptor mRNA was induced by etoposide in
HOC313 and Ca9-22 cells [42]. While the available
information on the involvement of caspase-8 function in
p53- and/or p73-dependent apoptosis is limited, cas-
pase-8-mediated cleavage of Bid has been observed dur-
ing p53-dependent apoptosis induced by neutron [46].
In addition, p53 has been shown to transactivate the
caspase-8 promoter [47], and p53-mediated up-regula-
tion of caspase-8 and sensitization toward death recep-
tor-mediated apoptosis was observed in certain tumor
cell lines with down-regulated caspase-8 as well as
TRAIL-resistant primary tumor cells following drug
treatment [48]. However, up-regulation of caspase-8
mRNA was not detected in p53-deficient Ca9-22 cells
following etoposide treatment (data not shown).
We show that p53/p73-dependent caspase-8 activation
is mediated by caspase-9 in etoposide-induced apoptosis
in HNSCC cells. Our results clearly demonstrate that
the caspase-9 inhibitor Ac-LEHD-CHO, or caspase-9
siRNA, blocked etoposide-induced apoptosis in both
HOC313/c8_3 and Ca9-22 cell lines. Consistent with
this, Ac-LEHD-CHO blocked caspase-8 activation, and
caspase-9 siRNA also blocked the cleavage of procas-
pase-8 and Bid, indicating that caspase-8 activation lies
downstream of the mitochondrial pathway, as reported
in previous studies [14-19]. In turn, caspase-8 activation
was required for p53/p73-dependent Bid cleavage, full
activation of caspase-9, and mitochondrial depolariza-
tion. In contrast, p53 restoration, by itself, induced little
if any mitochondrial depolarization, and no or weak
cleavage of procaspases-3 and -9 in caspase-8-deficient
HOC313/v_1 cells. In addition, there was no difference
in the expression level of Inhibitor of apoptosis proteins
(IAPs), such as Survivin, XIAP, and c-IAP, between
etoposide-sensitive Ca9-22 and -resistant HOC313 cells
(data not shown), indicating that caspase-8 loss does not
lead to the accumulation of IAPs in HOC313 cells.
Furthermore, the apoptotic inhibitor cellular FLICE-
inhibitory protein (c-FLIP) was not detected in etopo-
side-resistant HOC313 cells in both permissive and
non-permissive temperatures (data not shown). Thus,
results presented in this study are consistent with a
model in which the initial activation of caspase-9 is
amplified via caspase-8-mediated positive feedback loop,
which is required for the full activation of the caspases
in p53/p73-dependent apoptosis induced by etoposide in
HNSCC cells (Figure 8A). If this is the case, a dominant
negative mutant of FADD may not be able to rescue
etoposide-induced apoptosis in HNSCC cells. Alterna-
tively, it remains a possibility that caspase-8 might be
weakly activated by etoposide through the death recep-
tor pathway in HNSCC cells,a n dw o r k st o g e t h e rw i t h
p53/p73 in the caspase-8-mediated positive feedback
loop. Our results indicate that, in the absence of p53/
p73 functions, the amounts of cleaved caspase-8 and -9
are little, and thus caspase-8-mediated positive feedback
loop can not work in HNSCC cells.
Our results are also consistent with previous studies
indicating that p73 is a critical determinant of drug-
induced cell death in HNSCC [38,39]. We show that p73
siRNA blocked etoposide-induced apoptosis, procaspase-
8 cleavage, and caspase-3/7 activation in Ca9-22 cells.
Moreover, in line with a previous study demonstrating
that p73 induces mitochondria-mediated apoptosis
through PUMA transactivation [49], etoposide induced
p73 protein and Noxa and PUMA mRNA in Ca9-22
cells. These results indicate that, in the absence of func-
tional p53, p73 plays a key role in etoposide-induced
Figure 8 Model of the drug-specific activation of apoptotic
pathways in HNSCC cells. Caspase-8 plays critical roles in inducing
both death receptor- and mitochondria-mediated apoptosis in
HNSCC cells. The caspase-8-mediated signal amplification of the
mitochondrial pathway is important for determining the sensitivity
to etoposide-induced and p53/p73-mediated apoptosis (A).
Caspase-8 also mediates cisplatin-induced and death receptor-
mediated apoptosis (B) [42].
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regard, the reduction of p73 expression and lack of Noxa
and PUMA mRNA induction in etoposide-treated
HOC313 cells under non-permissive conditions of
p53G285K suggest that this attenuated p73 induction
contributes to etoposide resistance in HOC313 cells. In
agreement with this, the loss of p73 induction by geno-
toxic drugs has also been reported in chemoresistant
bladder and ovarian cancer cells [50,51]. Although the
mechanism underlying the attenuated induction of p73
in HOC313 cells is unclear, methylation-associated gene
silencing has been demonstrated in the p73 promoter in
leukemia cells [52]. Additionally, while p63 has been
shown to influence chemosensitivity in HNSCC cells
[40], the expression of neither the TA nor ΔNp 6 3i s o -
form was detected in HOC313 cells; in Ca9-22 cells,
while the protein levels of these isoforms were detectable,
but they did not change following drug treatment (data
not shown).
The apoptosis provoked by genotoxic drugs requires
the death-receptor and mitochondrial apoptotic pathways,
but which of the pathways is critical for the response to a
particular drug are not fully understood. Although the
precise signalling mechanisms underlying the response to
etoposide and cisplatin remains unclear at present, we
show that the signals upstream of caspase-8 activation
induced by cisplatin are different from those by etoposide
in HNSCC cells. The results presented here, together
with our previous study, demonstrate that p53/p73 func-
tion is dispensable for the caspase-8 activation and apop-
tosis induction by cisplatin. Furthermore, cisplatin was
less effective for the up-regulation of proapoptotic
p53-target genes and mitochondrial depolarization than
etoposide. Previous studies have demonstrated that cas-
pase-8 activation by genoto x i cd r u g si sm e d i a t e db y
death receptor signaling [5-10]. In line with this, we have
reported that cisplatin, but not etoposide induced death
ligand mRNA expression, such as TNF-a and TRAIL, in
Ca9-22 and HOC313 cells [42]. Furthermore, it has been
reported that the induction of TNF-a by NF-Bp l a y sa
critical role in cisplatin-induced apoptosis in HNSCC
cells [53]. Thus, our results support the view that cispla-
tin triggers apoptosis in a death receptor-dependent
manner in HNSCC cells (Figure 8B). Nevertheless, the
cleavage of procaspase-9 was observed in cisplatin-treated
HOC313/c8_3 cells, indicating the activation of the mito-
chondrial pathway during cisplatin-induced apoptosis.
However, the caspase-9 inhibitor Ac-LEHD-CHO had
only a slight effect on cisplatin-induced caspase-8 activa-
tion (Figure 5B, right panel).
Conclusions
The results presented here clearly demonstrate that p53
and p73 can act as upstream regulators of caspase-8,
and that caspase-8 plays a critical role for the execution
of the p53/p73-dependent apoptosis induced by etopo-
side in HNSCC cells. Our data suggest that caspase-
8-mediated feedback signal amplification is required for
full activation of the caspases in the p53/p73-dependent
apoptosis induced by etoposide in HNSCC cells.
Although caspase-8 mutation is rare in HNSCC, the
understanding of the molecular mechanisms underlying
chemoresistance in tumor cells may help to design new
strategies for chemotherapy. In this regard, these results
provide new insight into the molecular cascade of apop-
tosis signaling in HNSCC cells.
Methods
Cell culture
The human HNSCC cell lines HOC313 (p53G285K; cas-
pase-8R68X) [42] and Ca9-22 (p53R248W; caspase-8
wild type) were established at the Second Department of
Oral and Maxillofacial Surgery, Faculty of Dentistry,
Tokyo Medical and Dental University, and maintained
in our laboratory as described [54,55]. HOC313 deriva-
tive HOC313/c8_3 and control HOC313/v_1 cell lines
have been described previously [42]. All HNSCC cell
l i n e sa n dt h eS a o s - 2o s t e o s a r c o m ac e l ll i n ew e r em a i n -
tained in Dulbecco’s Modified Eagle’s Medium (Nissui
Pharmaceutical, Tokyo, Japan) supplemented with 10%
fetal bovine serum and gentamicin at 37°C (unless 32.5°
C is specifically indicated) in the presence of 5% CO2.
CAT assay
Saos-2 cells were transfected with 1 μgo fr e p o r t e rp l a s -
mid p53CONTK-CAT, together with 1 μgo fe i t h e r
pCMV-p53 or an empty vector. Twelve hours after
transfection, the cells were left at 37°C or shifted to
32.5°C. After continued incubation for 24 h, the cells
were subjected to CAT assay as previously described
[37]. The amounts of acetylated [14C] chloramphenicol
were quantitated using the Phosphor Autoradiography
System BAS2000 (Fuji Film, Tokyo, Japan).
Chemicals
Cisplatin (Wako, Osaka, Japan) and etoposide (Sigma-
Aldrich, St. Louis, MO) were dissolved in DMSO just
before use in each experiment. The caspase-9 inhibitor
Ac-LEHD-CHO and caspase-8 inhibitor Ac-IETD-CHO
were purchased from Peptide Institute (Osaka, Japan).
Western blotting
Western blotting analysis was performed as previously
described [38], using the following antibodies at dilu-
tions of 1: 500 to 1:1000: anti-p53 (sc-126), anti-p53-
phospho-ser15(# 9284), anti-p53-phospho-ser46 (#2521)
(Cell signaling technology, Beverly, MA), anti-p21
(sc-469, Santa Cruz Biotechnology, Santa Cruz, CA),
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pase-8 (clone 5F7, MBL, Nagoya, Japan), anti-PARP
(#9546), anti-caspase-9 (#9502), anti-Bid (#2002) (Cell
signaling technology, Beverly, MA), anti-caspase-3
(sc-7148), and anti-p73 antibodies (Ab-4, Neomarkers,
Fremont, CA).
Real-time reverse transcriptase PCR measurement of RNA
Total RNA was isolated by using TRI reagent (sigma)
according to the manufacturer’si n s t r u c t i o n s .R Tw a s
performed using 5 μg of total RNA using random pri-
mers and MMLV reverse transcriptase (TOYOBO,
Osaka, Japan). Quantitative real-time RT-PCR analysis
was performed on the LightCycler 480 instrument
(Roche Applied Science, Mannheim, Germany) in tripli-
cate using TaqMan Gene Expression Assays for PUMA,
Noxa, p21/CDKN1A, and 18s rRNA (Hs00248075_m1,
Hs00560402_m1, Hs00355782_m1, and Hs03003631_g1,
respectively) (Applied Biosystems, Foster City, CA, USA)
and the LightCycler 480 Probes Master kit (Roche
Applied Science), according to the manufacturer’s
instructions. The relative expression of mRNA, normal-
ized to 18srRNA, was calculated using the 2
(-ΔΔCP)
method.
WST-1 and caspase 3/7 and caspase-8 assays
Cells treated with increasing doses of anticancer drugs
were subjected to WST-1 assay as previously described
[38]. Cell viability was determined as a percentage of the
control. Data represent the average of six independent
experiments, each performed in triplicate. Caspase 3/7
and caspase-8 activity were determined using Caspase-
Glo 3/7 and Caspase-Glo 8 assay kits (Promega, Madi-
son, WI) according to the manufacturer’s instructions.
The data represent the average of three independent
experiments.
Cell cycle analysis
Drug-treated cells were fixed with 75% ethanol, and
then stained for DNA content as described previously
[39]. Cell cycle profiles were analyzed using a laser scan-
ning cytometer (LSC101; Olympus, Tokyo, Japan).
Plasmid
The expression vector for 3XFLAG caspase-8 WT
(pCMV-FLAG-caspase-8) has been described previously
[42]. The C360S mutation was introduced into pCMV-
FLAG-caspase-8 with appropriate mutagenesis primers.
The construct was confirmed by DNA sequencing.
Transient Transfection
HOC313 cells (3 × 10
6)w e r et r a n s f e c t e dw i t h6μgo f
each DNA construct using a pipette-type electroporator
(MicroPorator MP-100, Digital Bio) (pulse voltage; 1600
V, pulse width; 20 ms, pulse number; 1), and plated into
two 6 cm dishes. Twenty-four hours after transfection,
cells were treated with etoposide (100 μg/ml), then
harvested at the indicated time.
Measurement of mitochondrial membrane potential
The JC-1 mitochondrial membrane potential assay kit
(Cayman Chemical Co. Ann Arbor, MI) was used to
measure ΔΨm according to manufacturer’s instructions.
Cells were treated with drugs in 12-well plates for 10
hours, and then incubated with 0.1 volume of JC-1
Staining Solution to growth media for 15 min. There-
after, the cells were washed twice with supplied assay
buffer, and the plates were immediately read using a
multilabel counter (1420 ARVO MX, PerkinElmer,
Tokyo, Japan) with the excitation (Ex) and emission
(Em) wavelengths set at 530 nm Ex/590 nm Em for red
J-aggregate fluorescence, and 485 nm Ex/530 nm Em
for green fluorescence. The red/green fluorescence
ratios were calculated after the fluorescence values had
been corrected for the background.
siRNA transfection
Stealth siRNA duplexes targeting p73 (p73 siRNA-1:
5’-UCUGCUUGAAGGCACGCUUGCUGGC-3’ and
p73 siRNA-2: 5’-AGUACGUGUCCUCGUCUCCAUG
CCG-3’), Caspase-8 (Caspase-8 siRNA: 5’-AUAACA
UCAAGGCAUCCUUGAUGGG-3’), and Caspase-9
(Caspase-9 siRNA-1: 5’-AUGAUCAGCUGCCUGGC-
CUGA UCCC-3’ and Caspase-9 siRNA-2: 5’-UUUG-
CUGCUUGCCUGUUAGUUCGCA-3’), and negative
control duplexes (12935-400) were purchased from Invi-
trogen. Cells were reverse transfected with siRNA at
approximately 30-50% confluency using Lipofectamine
RNAiMAX (Invitrogen) according to the manufacturer’s
recommendations, and incubated for 48 hr prior to drug
treatment.
Statistical analysis
The data are expressed as the mean ± SD. Significance
was calculated using Student’s t-test. Values of P <0 . 0 5
were considered to be significant.
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